David Happel insider trades: Sagimet Biosciences (SGMT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | SGMT | ↓ Sell | 64,051 | $7.76 | $497K | Direct | Jul 22, 2026 (2d) |
| Feb 10, 2026 | SGMT | ↓ Sell | 12,101 | $5.36 | $65K | Direct | Feb 12, 2026 (2d) |
| Jul 21, 2025 | SGMT | ↓ Sell | 65,478 | $9.13 | $598K | Direct | Jul 23, 2025 (2d) |
| Mar 26, 2024 | SGMT | ↑ Buy | 12,100 | $5.27 | $64K | Direct | Mar 28, 2024 (2d) |
| Dec 7, 2023 | SGMT | ↑ Buy | 1,600 | $4.10 | $7K | Direct | Dec 8, 2023 (1d) |
| Nov 16, 2023 | SGMT | ↑ Buy | 590 | $2.35 | $1K | Direct | Nov 20, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SGMT insiders
Open-market trades in the last 12 months
About David Happel's insider trades
David Happel is President & CEO at Sagimet Biosciences (SGMT). Since Nov 16, 2023, David has reported 3 open-market purchases worth $72K and 3 sales worth $1.2M on SEC Form 4. In the last 12 months: 2 sales ($562K).
Their filings also include grants and awards (8 filings), shares returned to the company (2 filings), shares withheld for taxes (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SGMT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.